Phagenesis Ltd. raised $42 million in a series D financing round for its neurostimulation therapy, Phagenyx, which treats swallowing dysfunction. The funds will primarily support commercialization of the device in the U.S. where there is a huge unmet clinical need in dysphagia treatment, Reinhard Krickl, CEO of Phagenesis, told BioWorld.

Ocular gene therapy specialist Pulsesight Therapeutics SAS has launched with seed funding and is raising a series A to take forward two programs using electroporation to deliver plasmid DNA in the treatment of wet age-related macular degeneration and geographic atrophy.

Mainstay Medical Holdings plc raised $125 million in equity financing which it will use to conduct clinical trials and continue the commercial roll out of its Reactiv8 neurostimulation therapy that treats chronic lower back pain.

Osang Healthcare Co. Ltd. is attempting a second listing on the Kosdaq market with an IPO, planned sometime in March, to fund the company’s growth beyond the COVID-19 pandemic.